Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Vericel Corp | a57191exv23w1.htm |
| EX-31.1 - EX-31.1 - Vericel Corp | a57191exv31w1.htm |
| 10-K - FORM 10-K - Vericel Corp | a57191e10vk.htm |
| EX-21 - EX-21 - Vericel Corp | a57191exv21.htm |
| EX-31.2 - EX-31.2 - Vericel Corp | a57191exv31w2.htm |
EXHIBIT 32.1
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Aastrom Biosciences, Inc. (the “Company”) on Form 10-K
for the year ended June 30, 2010, as filed with the Securities and Exchange Commission on the date
hereof (the “Report”), each of the undersigned officers of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 (“Section 906”), the following:
(1) The Report fully complies with the requirements of section 13(a) and 15(d) of the
Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
| /s/ Timothy M. Mayleben
|
||||
| President and Chief Executive Officer | ||||
| (Principal Executive Officer) | ||||
| /s/ Scott C. Durbin
|
||||
| Chief Financial Officer | ||||
| (Principal Financial and Accounting Officer) |
Date: September 7, 2010
A signed original of this written statement required by Section 906 has been provided to Aastrom
Biosciences, Inc. and will be retained by Aastrom Biosciences, Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.